Innovative therapies for neovascular age-related macular degeneration

References

• Friedman DS, O’Colmain BJ, Munoz B, et al. Prevalence of age-related macular degeneration in the United States. Arch Ophtalmol. 2004 Apr;122(4):564–572.
   PubMed Web of Science ®Google Scholar
• Owen CG, Jarrar Z, Wormald R, et al. The estimated prevalence and incidence of late stage age related macular degeneration in the UK. Br J Ophthalmol. 2012 May;96(5):752–756.
   PubMed Web of Science ®Google Scholar
• Ferris FL III, Fine SL, Hyman L. Age-related macular degeneration and blindness due to neovascular maculopathy. Arch Ophtalmol. 1984;102(11):1640–1642.
   PubMed Web of Science ®Google Scholar
• Donald J, Gass M. Pathogenesis of disciform detachment of the neuroepithelium: I. general concepts and classification. Am J Ophthalmol. 1967 Mar 01;63(3, Part 2):573/1–85/13.
   Google Scholar
• Green WR, Enger C. Age-related macular degeneration histopathologic studies: the 1992 Lorenz E. Zimmerman Lecture. Ophthalmology. 1993;100(10):1519–1535.
   PubMed Web of Science ®Google Scholar
• Leung D, Cachianes G, Kuang W, et al. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science. 1989;246(4935):1306–1309.
   PubMed Web of Science ®Google Scholar
• Senger DR, Galli SJ, Dvorak AM, et al. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science. 1983 Feb 25;219(4587):983–985.
   PubMed Web of Science ®Google Scholar
• Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006 Oct 05;355(14):1419–1431.
   PubMed Web of Science ®Google Scholar
• Heier JS, Brown DM, Chong V, et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012 Dec;119(12):2537–2548.
   PubMed Web of Science ®Google Scholar
• Barthelmes D, Nguyen V, Daien V, et al. Two year outcomes of “Treat and Extend” intravitreal therapy using aflibercept preferentially for neovascular age-related macular degeneration. Retina. 2018 Jan;38(1):20–28.
   Web of Science ®Google Scholar
• Arevalo JF, Lasave AF, Wu L, et al. Intravitreal bevacizumab for choroidal neovascularization in age-related macular degeneration: 5-year results of The Pan-American Collaborative Retina Study Group. Retina. 2016 May;36(5):859–867.
   Google Scholar
• Cohen SY, Mimoun G, Oubraham H, et al. Changes in visual acuity in patients with wet age-related macular degeneration treated with intravitreal ranibizumab in daily clinical practice: the LUMIERE study. Retina. 2013 Mar;33(3):474–481.
   PubMed Web of Science ®Google Scholar
• Hjelmqvist L, Lindberg C, Kanulf P, et al. One-year outcomes using ranibizumab for neovascular age-related macular degeneration: results of a prospective and retrospective observational multicentre study. J Ophthalmol. 2011;405724.
   PubMedGoogle Scholar
• Holz FG, Tadayoni R, Beatty S, et al. Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration. Br J Ophthalmol. 2015 Feb;99(2):220–226.
   PubMed Web of Science ®Google Scholar
• Kruger Falk M, Kemp H, Sorensen TL. Four-year treatment results of neovascular age-related macular degeneration with ranibizumab and causes for discontinuation of treatment. Am J Ophthalmol. 2013 Jan;155(1):89–95 e3.
   PubMed Web of Science ®Google Scholar
• Rakic JM, Leys A, Brie H, et al. Real-world variability in ranibizumab treatment and associated clinical, quality of life, and safety outcomes over 24 months in patients with neovascular age-related macular degeneration: the HELIOS study. Clin Ophthalmol. 2013;7:1849–1858.
   PubMedGoogle Scholar
• Rasmussen A, Bloch SB, Fuchs J, et al. A 4-year longitudinal study of 555 patients treated with ranibizumab for neovascular age-related macular degeneration. Ophthalmology. 2013 Dec;120(12):2630–2636.
   PubMed Web of Science ®Google Scholar
• Souied EH, Oubraham H, Mimoun G, et al. Changes in visual acuity in patients with wet age-related macular degeneration treated with intravitreal ranibizumab in daily clinical practice: the TWIN study. Retina. 2015 Sep;35(9):1743–1749.
   PubMed Web of Science ®Google Scholar
• Talks JS, Lotery AJ, Ghanchi F, et al. First-year visual acuity outcomes in the United Kingdom of providing aflibercept according to the VIEW study protocol for age-related macular degeneration. Ophthalmology. 2016 Feb;123(2):337–343.
   PubMed Web of Science ®Google Scholar
• van Asten F, Evers-Birkenkamp KU, van Lith-Verhoeven JJ, et al. A prospective, observational, open-label, multicentre study to investigate the daily treatment practice of ranibizumab in patients with neovascular age-related macular degeneration. Acta Ophthalmol. 2015 Mar;93(2):126–133.
   PubMed Web of Science ®Google Scholar
• Writing Committee for the U. K. Age-Related Macular Degeneration E. M. R. Users Group. The neovascular age-related macular degeneration database: multicenter study of 92 976 ranibizumab injections: report 1: visual acuity. Ophthalmology. 2014 May;121(5):1092–1101.
   PubMed Web of Science ®Google Scholar
• Zarranz-Ventura J, Liew G, Johnston RL, et al. The neovascular age-related macular degeneration database: report 2: incidence, management, and visual outcomes of second treated eyes. Ophthalmology. 2014 Oct;121(10):1966–1975.
   PubMed Web of Science ®Google Scholar
• Ross AH, Donachie PH, Sallam A, et al. Which visual acuity measurements define high-quality care for patients with neovascular age-related macular degeneration treated with ranibizumab? Eye (Lond). 2013 Jan;27(1):56–64.
   PubMed Web of Science ®Google Scholar
• Rao P, Lum F, Wood K, et al. Real-world vision in age-related macular degeneration patients treated with single anti-VEGF drug type for 1 year in the IRIS registry. Ophthalmology. 2018;125:522–528.
   PubMed Web of Science ®Google Scholar
• Ciulla TA, Hussain RM, Pollack JS, et al. Visual Acuity outcomes and anti-vascular endothelial growth factor therapy intensity in neovascular AMD patients: a “Real World” analysis in 49,485 eyes. Ophthalmol Retina. 2019. [ Epub ahead of print]
   PubMedGoogle Scholar
• Dadgostar H, Ventura AA, Chung JY, et al. Evaluation of injection frequency and visual acuity outcomes for ranibizumab monotherapy in exudative age-related macular degeneration. Ophthalmology. 2009 Sep;116(9):1740–1747.
   PubMed Web of Science ®Google Scholar
• Hussain RM, Hariprasad SM, Ciulla TA. Treatment burden in neovascular AMD:visual acuity outcomes are associated with anti-VEGF injection frequency. Ophthalmic Surg Lasers Imaging Retina. 2017 Oct 1;48(10):780–784.
   PubMed Web of Science ®Google Scholar
• Smith AG, Kaiser PK. Emerging treatments for wet age-related macular degeneration. Expert Opin Emerg Drugs. 2014 Mar;19(1):157–164.
   PubMed Web of Science ®Google Scholar
• Daniel E, Toth CA, Grunwald JE, et al. Risk of scar in the comparison of age-related macular degeneration treatments trials. Ophthalmology. 2014 Mar;121(3):656–666.
   PubMed Web of Science ®Google Scholar
• Miller JW, Le Couter J, Strauss EC, et al. Vascular endothelial growth factor a in intraocular vascular disease. Ophthalmology. 2013 Jan;120(1):106–114.
   PubMed Web of Science ®Google Scholar
• Holmes DI, Zachary I. The vascular endothelial growth factor (VEGF) family: angiogenic factors in health and disease. Genome Biol. 2005;6(2):209.
   PubMed Web of Science ®Google Scholar
• Gerber HP, McMurtrey A, Kowalski J, et al. Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3ʹ-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. J Biol Chem. 1998 Nov 13;273(46):30336–30343.
   PubMed Web of Science ®Google Scholar
• Kim I, Moon SO, Kim SH, et al. Vascular endothelial growth factor expression of intercellular adhesion molecule 1 (ICAM-1), vascular cell adhesion molecule 1 (VCAM-1), and E-selectin through nuclear factor-kappa B activation in endothelial cells. J Biol Chem. 2001 Mar 09;276(10):7614–7620.
   PubMed Web of Science ®Google Scholar
• Jo N, Mailhos C, Ju M, et al. Inhibition of platelet-derived growth factor B signaling enhances the efficacy of anti-vascular endothelial growth factor therapy in multiple models of ocular neovascularization. Am J Pathol. 2006 Jun;168(6):2036–2053.
   PubMed Web of Science ®Google Scholar
• Erber R, Thurnher A, Katsen AD, et al. Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms. Faseb J. 2004 Feb;18(2):338–340.
   PubMed Web of Science ®Google Scholar
• Benjamin LE, Hemo I, Keshet E. A plasticity window for blood vessel remodelling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF. Development. 1998 May;125(9):1591–1598.
   PubMed Web of Science ®Google Scholar
• Armulik A, Abramsson A, Betsholtz C. Endothelial/pericyte interactions. Circ Res. 2005 Sep 16;97(6):512–523.
   PubMed Web of Science ®Google Scholar
• Hellstrom M, Kalen M, Lindahl P, et al. Role of PDGF-B and PDGFR-beta in recruitment of vascular smooth muscle cells and pericytes during embryonic blood vessel formation in the mouse. Development. 1999 Jun;126(14):3047–3055.
   PubMed Web of Science ®Google Scholar
• Davis S, Yancopoulos GD. The angiopoietins: yin and Yang in angiogenesis. Curr Top Microbiol Immunol. 1999;237:173–185.
   PubMed Web of Science ®Google Scholar
• Bhattacharya D, Chaudhuri S, MK S, et al. T11TS inhibits Angiopoietin-1/Tie-2 signaling, EGFR activation and Raf/MEK/ERK pathway in brain endothelial cells restraining angiogenesis in glioma model. Exp Mol Pathol. 2015 june 01;98(3):455–466.
   PubMed Web of Science ®Google Scholar
• Hansen TM, Singh H, Tahir TA, et al. Effects of angiopoietins-1 and −2 on the receptor tyrosine kinase Tie2 are differentially regulated at the endothelial cell surface. Cell Signal. 2010 Mar;22(3):527–532.
   PubMed Web of Science ®Google Scholar
• Fachinger G, Deutsch U, Risau W. Functional interaction of vascular endothelial-protein-tyrosine phosphatase with the angiopoietin receptor Tie-2. Oncogene. 1999 Oct 21;18:5948. online.
   PubMed Web of Science ®Google Scholar
• Dugel PU. Phase 3, randomized, double-masked, multicenter trials of brolucizumab vs. aflibercept for neovascular AMD: ninety-six-week results from the HAWK and HARRIER studies. Chicago: American Academy of Ophthalmology;2018.
   Google Scholar
• Dugel PU. HAWK & HARRIER: 48-week results of 2 multi-centered, randomized, double-masked trials of brolucizumab versus aflibercept for neovascular AMD. New Orleans: American Academy of Ophthalmology; 2017.
   Google Scholar
• Allergan and molecular partners announce two positive phase 3 clinical trials for abicipar pegol 8 and 12-week regimens for the treatment in patients with neovascular age-related macular degeneration; 2019. Available from: https://www.molecularpartners.com/allergan-and-molecular-partners-announce-two-positive-phase-3-clinical-trials-for-abicipar-pegol-8-and-12-week-regimens-for-the-treatment-in-patients-with-neovascular-age-related-macular-degeneration/
   Google Scholar
• Kirker RM. CLINICAL TRIAL CLOSEUP: A deeper dive into abicipar trials; 2018. [cited 2019 Jun 10]. Available from: http://www.retina-specialist.com/article/a-deeper-dive-into-abicipar-trials
   Google Scholar
• Allergan and Molecular Partners Announce Topline Safety Results from MAPLE study of Abicipar pegol; 2019. [cited 2019 Jun 10]. Available from: https://www.allergan.com/news/news/thomson-reuters/allergan-and-molecular-partners-announce-topline-s.aspx
   Google Scholar
• Liu K, Song Y, Xu G, et al. Conbercept for Treatment of Neovascular Age-related Macular Degeneration: results of the Randomized Phase 3 PHOENIX Study. Am J Ophthalmol. 2019;197:156–167.
   PubMed Web of Science ®Google Scholar
• Kodiak sciences announces completion of 12-week phase 1a study of KSI-301 in patients with diabetic macular edema demonstrating safety and durability of responses following single dose of intravitreal anti-VEGF antibody biopolymer conjugate; 2018. [cited 2019 Mar 17]. Available from: https://www.prnewswire.com/news-releases/kodiak-sciences-announces-completion-of-12-week-phase-1a-study-of-ksi-301-in-patients-with-diabetic-macular-edema-demonstrating-safety-and-durability-of-responses-following-single-dose-of-intravitreal-anti-vegf-antibody-biopolymer-300770093.html
   Google Scholar
• Jaffe GJ, Ciulla TA, Ciardella AP, et al. Dual Antagonism of PDGF and VEGF in neovascular age-related macular degeneration: A phase IIb, multicenter, randomized controlled trial. Ophthalmology. 2017 Feb;124(2):224–234.
   PubMed Web of Science ®Google Scholar
• Ophthotech announces results from pivotal phase 3 trials of Fovista® in wet age-related macular degeneration; 2016 [cited 2017 Feb 27]. Available from: http://investors.ophthotech.com/releasedetail.cfm?ReleaseID=1003651
   Google Scholar
• Dunn EN, Hariprasad SM, Sheth VS. An overview of the Fovista and rinucumab trials and the fate of anti-PDGF medications. Ophthalmic Surg Lasers Imaging Retina. 2017 Feb 01;48(2):100–104.
   PubMed Web of Science ®Google Scholar
• Regeneron announces phase 2 study of aflibercept co-formulated with rinucumab (anti-PDGFR-beta) shows no benefit over aflibercept alone in neovascular age-related macular degeneration; 2016. [cited 2019 Feb 26]. Available from: http://investor.regeneron.com/releasedetail.cfm?releaseid=991601
   Google Scholar
• Jackson TL, Boyer D, Brown DM, et al. Oral tyrosine kinase inhibitor for neovascular age-related macular degeneration: A phase 1 dose-escalation study. JAMA Ophthalmol. 2017 Jun 01;135:761.
   Web of Science ®Google Scholar
• Brown DM. Phase 1 study of combination therapy with nesvacumab and aflibercept for neovascular AMD and diabetic macular edema. American Academy of Ophthalmology annual meeting; 2016; Chicago, IL.
   Google Scholar
• Boyer DS. Aflibercept combination therapies: rinucumab/aflibercept and nesvacumab/aflibercept. Chicago, IL: American Academy of Ophthalmology; 2016.
   Google Scholar
• Helzner J. Faricimab Shows Potential for 16-Week Dosing. Retin Physician. 2018 September.
   Google Scholar
• Khanani AM. Simultaneous inhibition of VEGF and Ang-2 with faricimab in neovascular AMD: STAIRWAY phase 2 results. Chicago: American Academy of Ophthalmology; 2018.
   Google Scholar
• Csaky KG, Dugel PU, Pierce AJ, et al. Clinical evaluation of pazopanib eye drops versus ranibizumab intravitreal injections in subjects with neovascular age-related macular degeneration. Ophthalmology. 2015 Mar;122(3):579–588.
   PubMed Web of Science ®Google Scholar
• Joussen A, Wolf S, Kaiser PK. A combined phase 2a/b study of the efficacy, safety, and tolerability of repeated topical doses of regorafenib eye drops in treatment-naïve patients with neovascular age-related macular degeneration (nAMD). Seattle, WA: Association for Research in Vision and Ophthalmology; 2016.
   Google Scholar
• LHA510 proof-of-concept study as a maintenance therapy for patients with wet age-related macular degeneration. [cited 2019 Jan 19]. Available from: https://clinicaltrials.gov/ct2/show/NCT02355028
   Google Scholar
• Panoptica doses first patient with new formulation of PAN-90806, a novel, topical anti-VEGF eye drop, in phase 1/2 clinical trial; 2018. [cited 2019 Mar 22]. Available from: http://www.panopticapharma.com/wp-content/uploads/2018/05/PanOptica-New-Formulation-First-Patient-Dosed-News-Release-Final-May-17-2018.pdf
   Google Scholar
• Rubio RG. Long-acting anti-VEGF delivery. Retina Today. 2014 July/August.
   PubMedGoogle Scholar
• LADDER trial of the port delivery system for ranibizumab: preliminary study results. Vancouver: American Society of Retina Specialists; 2018.
   Google Scholar
• Graybug vision presents top line results of phase 1/2a ADAGIO study at Hawaiian eye & retina 2019; 2019. [cited 2019 Mar 24]. Available from: https://graybug.com/graybug-vision-presents-top-line-results-of-phase-1-2a-adagio-study-at-hawaiian-eye-retina-2019/
   Google Scholar
• NT-503 ECT. [cited 2019 Mar 25]. Available from: http://www.neurotechusa.com/nc-503-ect.html
   Google Scholar
• Pipeline - Ocular Therapeutix. [cited 2019 Mar 05]. Available from: https://www.ocutx.com/research/pipeline/
   Google Scholar
• Lurker N. pSivida corp. Ophthalmic Innoviations Summit at American Academy of Ophthalmology meeting; 2016; Chicago, IL.
   Google Scholar
• Rakoczy EP, Lai CM, Magno AL, et al. Gene therapy with recombinant adeno-associated vectors for neovascular age-related macular degeneration: 1 year follow-up of a phase 1 randomised clinical trial. Lancet. 2015 Dec 12;386(10011):2395–2403.
   PubMed Web of Science ®Google Scholar
• Constable IJ, Lai CM, Magno AL, et al. Gene therapy in neovascular age-related macular degeneration: three-year follow-up of a phase 1 randomized dose escalation trial. Am J Ophthalmol. 2017;177:150–158.
   PubMed Web of Science ®Google Scholar
• Constable IJ, Pierce CM, Lai CM, et al. Phase 2a randomized clinical trial: safety and Post Hoc Analysis of subretinal rAAV.sFLT-1 for wet age-related macular degeneration. EBioMedicine. 2016 Dec;14:168–175.
   PubMed Web of Science ®Google Scholar
• Adverum Biotechnologies provides update on OPTIC phase 1 trial for ADVM-022 in wet AMD; 2019. [cited 2019 Mar 25]. Available from: http://investors.adverum.com/news-releases/news-release-details/adverum-biotechnologies-provides-update-optic-phase-1-trial-advm
   Google Scholar
• Heier JS, Kherani S, Desai S, et al. Intravitreous injection of AAV2-sFLT01 in patients with advanced neovascular age-related macular degeneration: a phase 1, open-label trial. Lancet. 2017 Jul 1;390(10089):50–61.
   PubMed Web of Science ®Google Scholar
• Corporate Presentation. 2019. [cited 2019 Jun 03]. Available from: https://regenxbio.gcs-web.com/static-files/3e73040c-8f46-4353-9653-7e643f3bc59d
   Google Scholar
• REGENXBIO REPORTS CONTINUED PROGRESS ACROSS PROGRAMS IN YEAR-END 2018 CORPORATE UPDATE; 2019. [cited 2019 Feb 23]. Available from: https://regenxbio.gcs-web.com/news-releases/news-release-details/regenxbio-reports-continued-progress-across-programs-year-end
   Google Scholar
• REGENXBIO ANNOUNCES COMPLETION OF DOSING FOR PHASE I/IIA CLINICAL TRIAL OF RGX-314 IN WET AMD; 2019. [cited 2019 Jun 04]. Available from: https://regenxbio.gcs-web.com/news-releases/news-release-details/regenxbio-announces-completion-dosing-phase-iiia-clinical-trial
   Google Scholar
• Binley K, Widdowson PS, Kelleher M, et al. Safety and biodistribution of an equine infectious anemia virus-based gene therapy, RetinoStat((R)), for age-related macular degeneration. Hum Gene Ther. 2012 Sep;23(9):980–991.
   PubMed Web of Science ®Google Scholar
• Lai CM, Estcourt MJ, Himbeck RP, et al. Preclinical safety evaluation of subretinal AAV2.sFlt-1 in non-human primates. Gene Ther. 2012 Oct;19(10):999–1009.
   PubMed Web of Science ®Google Scholar
• Igarashi T, Miyake K, Kato K, et al. Lentivirus-mediated expression of angiostatin efficiently inhibits neovascularization in a murine proliferative retinopathy model. Gene Ther. 2003 Feb;10(3):219–226.
   PubMed Web of Science ®Google Scholar
• Campochiaro PA, Lauer AK, Sohn EH, et al. Lentiviral vector gene transfer of endostatin/angiostatin for macular degeneration (GEM) study. Hum Gene Ther. 2017 Jan;28(1):99–111.
   PubMed Web of Science ®Google Scholar
• Moja L, Lucenteforte E, Kwag KH, et al. Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration. Cochrane Database Syst Rev. 2014 Sep;15(9):CD011230.
   Google Scholar
• Bracha P, Moore NA, Ciulla TA, et al. The acute and chronic effects of intravitreal anti-vascular endothelial growth factor injections on intraocular pressure: A review. Surv Ophthalmol. 2018 May–Jun;63(3):281–295.
   PubMed Web of Science ®Google Scholar
• Baek SU, Park IW, Suh W. Long-term intraocular pressure changes after intravitreal injection of bevacizumab. Cutan Ocul Toxicol. 2016 Dec;35(4):310–314.
   PubMed Web of Science ®Google Scholar
• Rayess N, Rahimy E, Storey P, et al. Postinjection endophthalmitis rates and characteristics following intravitreal Bevacizumab, ranibizumab, and aflibercept. Am J Ophthalmol. 2016;165:88–93.
   PubMed Web of Science ®Google Scholar
• Chang LK, Sarraf D. Tears of the retinal pigment epithelium: an old problem in a new era. Retina. 2007 Jun;27(5):523–534.
   PubMed Web of Science ®Google Scholar
• Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006 Oct 05;355(14):1432–1444.
   PubMed Web of Science ®Google Scholar
• Berg K, Pedersen TR, Sandvik L, et al. Comparison of ranibizumab and bevacizumab for neovascular age-related macular degeneration according to LUCAS treat-and-extend protocol. Ophthalmology. 2015 Jan;122(1):146–152.
   PubMed Web of Science ®Google Scholar
• Wykoff CC, Croft DE, Brown DM, et al. Prospective trial of treat-and-extend versus monthly dosing for neovascular age-related macular degeneration: TREX-AMD 1-year results. Ophthalmology. 2015 Dec;122(12):2514–2522.
   PubMed Web of Science ®Google Scholar